VCM
PACB icon

Vivaldi Capital Management’s Pacific Biosciences PACB Stock Holding History

Vivaldi Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-16,343
Closed -$121K – 236
2018
Q4 		$121K Buy
+16,343
New +$104K 0.05% 184

Other funds holding PACB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Vivaldi Capital Management's PACB Position: Q1 2019 in Review

Vivaldi Capital Management sold out of Pacific Biosciences (PACB) in Q1 2019, closing a stake of 16,343 shares — an estimated $121K sold.

Vivaldi Capital Management first reported a position in PACB in Q4 2018 and held it in 1 quarter. The position peaked at $121K in Q4 2018. 160 funds tracked by Wall St. Rank hold PACB as of Q1 2019.

  • Vivaldi Capital Management reported no remaining Pacific Biosciences position as of Q1 2019 after selling out during the quarter.
  • Vivaldi Capital Management sold 16,343 Pacific Biosciences shares in Q1 2019, an estimated $121K.
  • Vivaldi Capital Management first reported a position in Pacific Biosciences in Q4 2018 and held it in 1 quarter.
  • Vivaldi Capital Management's Pacific Biosciences position peaked at $121K in Q4 2018.
  • 160 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2019.

Based on Vivaldi Capital Management's 13F filing for Q1 2019, filed 15 May 2019.